276 related articles for article (PubMed ID: 15280205)
21. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
[TBL] [Abstract][Full Text] [Related]
22. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
23. The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.
Palathumpat V; Dejbakhsh-Jones S; Strober S
Transplantation; 1995 Aug; 60(4):355-61. PubMed ID: 7652765
[TBL] [Abstract][Full Text] [Related]
24. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
[TBL] [Abstract][Full Text] [Related]
25. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
[TBL] [Abstract][Full Text] [Related]
26. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD.
Yang YG; Sykes M
Leuk Lymphoma; 1999 May; 33(5-6):409-20. PubMed ID: 10342569
[TBL] [Abstract][Full Text] [Related]
27. Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling.
Li JM; Petersen CT; Li JX; Panjwani R; Chandra DJ; Giver CR; Blazar BR; Waller EK
Cancer Res; 2016 Dec; 76(23):6802-6815. PubMed ID: 27671676
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
29. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
30. CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD.
Dutt S; Baker J; Kohrt HE; Kambham N; Sanyal M; Negrin RS; Strober S
Blood; 2011 Mar; 117(11):3230-9. PubMed ID: 21239702
[TBL] [Abstract][Full Text] [Related]
31. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease.
Zhang Y; Shlomchik WD; Joe G; Louboutin JP; Zhu J; Rivera A; Giannola D; Emerson SG
J Immunol; 2002 Dec; 169(12):7111-8. PubMed ID: 12471148
[TBL] [Abstract][Full Text] [Related]
32. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
33. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.
Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL
Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661
[TBL] [Abstract][Full Text] [Related]
34. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
Hossain MS; Roback JD; Lezhava L; Hillyer CD; Waller EK
Biol Blood Marrow Transplant; 2005 Mar; 11(3):169-80. PubMed ID: 15744235
[TBL] [Abstract][Full Text] [Related]
35. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
Olson JA; Leveson-Gower DB; Gill S; Baker J; Beilhack A; Negrin RS
Blood; 2010 May; 115(21):4293-301. PubMed ID: 20233969
[TBL] [Abstract][Full Text] [Related]
36. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
[TBL] [Abstract][Full Text] [Related]
37. [Effects of natural killer cells on engraftment and reconstitution of hematopoiesis and immunity in mice undergoing allogeneic bone marrow transplantation].
Yang ZG; Xiong D; Zeng YY; Liang L; Li QH; Wu GC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):627-32. PubMed ID: 18549643
[TBL] [Abstract][Full Text] [Related]
38. The effect of the spleen on compartmental levels and distribution of donor progenitor cells after syngeneic and allogeneic bone marrow transplants.
Shatry AM; Jones M; Levy RB
Stem Cells Dev; 2004 Feb; 13(1):51-62. PubMed ID: 15068693
[TBL] [Abstract][Full Text] [Related]
39. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
40. [The role of IL-22 on thymus recovery and its function in mice following allogeneic bone marrow transplantation].
Zhao K; Zhao D; Yin L; Pan B; Xu K
Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):822-5. PubMed ID: 25246251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
